Muraglitazar
Muraglitazar
Muraglitazar (pronunciation: muh-rah-glih-tah-zar) is a pharmaceutical drug that was developed for the treatment of Type 2 diabetes and dyslipidemia. It belongs to the class of drugs known as dual PPAR agonists, which work by activating two types of peroxisome proliferator-activated receptors (PPARs), specifically PPAR-alpha and PPAR-gamma.
Etymology
The name "Muraglitazar" is derived from the combination of the words "murine" and "glitazar". "Murine" refers to the drug's initial testing in mice, while "glitazar" is a common suffix for drugs that act as PPAR agonists.
Pharmacology
Muraglitazar works by activating PPAR-alpha and PPAR-gamma, two types of peroxisome proliferator-activated receptors. PPAR-alpha activation leads to an increase in the breakdown and removal of fats, while PPAR-gamma activation helps to regulate blood sugar levels. This dual action makes Muraglitazar effective in treating both dyslipidemia and Type 2 diabetes.
Development and Approval
Muraglitazar was developed by Bristol-Myers Squibb, a global biopharmaceutical company. However, despite showing promise in early clinical trials, the drug was not approved by the Food and Drug Administration (FDA) due to concerns about its safety profile, specifically an increased risk of cardiovascular events.
Related Terms
- Dual PPAR agonists
- Type 2 diabetes
- Dyslipidemia
- Peroxisome proliferator-activated receptors
- Bristol-Myers Squibb
- Food and Drug Administration
External links
- Medical encyclopedia article on Muraglitazar
- Wikipedia's article - Muraglitazar
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski